Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
FOAmicus Therapeutics, Inc. logo

Amicus Therapeutics, Inc. (FOLD)

NASDAQ Global Market · Currency in USD
$14.49 ▲ +0.00 (+0.00%)
At close: Apr 27, 4:00 PM ET. Market closed.

Summary

Previous Close
$14.49
Open
$14.49
Day's Range
$14.49 – $14.49
52 Week Range
$5.51 – $14.50
Volume
0
Avg. Volume
4,150,713
Market Cap
$4.55B
Beta (5Y Monthly)
0.48
PE Ratio (TTM)
--
EPS (TTM)
-$0.02
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$14.86

Profile: Amicus Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
499
CEO
Bradley L. Campbell

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3.

Earnings

DateEst.Actual
Feb 20, 2026$0.07$0.01Miss
Nov 4, 2025$0.04$0.06Beat
Jul 31, 2025-$0.05-$0.08Miss
May 1, 2025$0.01-$0.07Miss
Feb 19, 2025$0.02$0.09Beat
Nov 6, 2024$0.00-$0.02Miss

Analyst view

Consensus price target
$14.86 ▲ +2.6%
Range $13.00 – $19.00
Rating: Buy
Buy 67% · Hold 29% · Sell 4%

Get free alerts on FOLD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.